53BP2 (19): sc-135818



The Power to Question

BACKGROUND

The p53 binding proteins 53BP1 and 53BP2 (Bbp) bind to the central DNA-binding domain of wild type p53, but do not bind mutant p53. The central DNA-binding domain of p53 is required for site-specific DNA binding and is frequently mutated in malignant tumors. Binding of 53BP1 to the L3 loop of p53 and of 53BP2 to the L2 loop of p53 confirms that the loop is dependent on p53 conformation. Site-specific binding also suggests that 53BP1 and 53BP2 are involved in p53-mediated tumor suppression. 53BP1 was isolated from H258 cells and is expressed in Jurkat cells in both the cytoplasm and the nucleus. The N-terminus of 53BP2 is localized to the cytoplasm, while the C-terminus might be localized in the nucleus. 53BP1 promotes cell proliferation by binding to p202, whereas 53BP2 induces cell death by binding to Bcl-2 and NF κ B p65.

REFERENCES

- 1. Iwabuchi, K., et al. 1994. Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. USA 91: 6098-6102.
- Gorina, S., et al. 1996. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274: 1001-1005.
- Naumovski, L., et al. 1996. The p53-binding protein 53BP2 also interacts with Bcl-12 and impedes cell cycle progression at G₂/M. Mol. Cell. Biol. 16: 3884-3892.
- 4. Bansidhar, D., et al. 1996. p202, an interferon-inducible modulator of transcription, inhibits transcriptional activation by the p53 tumor suppressor protein and a segment from the p53-binding protein 1 that binds to p202 overcomes this inhibition. J. Biol. Chem. 271: 27544-27555.
- Iwabuchi, K., et al. 1998. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J. Biol. Chem. 273: 26061-26068.
- Yang, J.P., et al. 1999. NFκB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 18: 5177-5186.

CHROMOSOMAL LOCATION

Genetic locus: TP53BP2 (human) mapping to 1q41.

SOURCE

53BP2 (19) is a mouse monoclonal antibody raised against amino acids 674-793 of 53BP2 of human origin.

PRODUCT

Each vial contains 50 μg lgG_1 in 0.5 ml of PBS with < 0.1% sodium azide, 0.1% gelatin, 20% glycerol and 0.04% stabilizer protein.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures. Not for resale.

APPLICATIONS

53BP2 (19) is recommended for detection of 53BP2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)] and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).


Suitable for use as control antibody for 53BP2 siRNA (h): sc-37457, 53BP2 shRNA Plasmid (h): sc-37457-SH and 53BP2 shRNA (h) Lentiviral Particles: sc-37457-V.

Molecular Weight of 53BP2 short isoform: 137 kDa.

Molecular Weight of 53BP2 long isoform: 150 kDa.

Positive Controls: WI-38 whole cell lysate: sc-364260

DATA



53BP2 (19): sc-135818. Immunofluorescence staining of human endothelial cells showing cytoplasmic staining

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com